A phase 2B clinical trial to study the efficacy of longeveron mesenchymal stem cells (lmscs) to treat aging frailty
Ended Project Grant Awarded Last action
- Award ID
- R44AG062015
- Recipient
-
Longeveron Inc. UEI PYXXAC2HV5T3
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,240,853
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date
- Originally
- Place of performance
- Miami, FL 33136, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $1,974,282 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,983,531 | |
| Amendment | $0 | |
| Original award | $283,040 |
Quick answers
Who received award R44AG062015?
R44AG062015 was awarded to Longeveron Inc. by National Institute on Aging (National Institutes of Health) on September 30, 2018.
How much is award R44AG062015 worth?
$4,240,853 has been obligated on R44AG062015.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award